Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27540690 | 0.77 | GRM4 (0.57) | KDRKCNK3KCNK9CES1GRM4 | |
| SCHEMBL7401799 | 0.77 | NPC1 (0.53) | KDRKCNK3KCNK9CES1GRM4 | |
| SCHEMBL28790278 | 0.76 | KDR (0.64) | KDRKCNK3KCNK9GRM4HDAC6 | |
| SCHEMBL29289285 | 0.75 | TLR7 (0.58) | KDRCES1MEN1KMT2ATLR7 | |
| SCHEMBL993580 | 0.75 | MEN1 (0.64) | KDRKCNK3KCNK9CES1MEN1 | |
| SCHEMBL994629 | 0.75 | MEN1 (0.64) | KDRKCNK3KCNK9CES1MEN1 | |
| SCHEMBL27555176 | 0.75 | MEN1 (0.64) | KDRKCNK3KCNK9CES1MEN1 | |
| SCHEMBL9336728 | 0.74 | KDM4E (0.55) | KCNK3KCNK9GRM4KMT2AKDM4E | |
| SCHEMBL994977 | 0.74 | GRM5 (0.59) | KDRCES1MEN1KMT2A | |
| SCHEMBL3674558 | 0.74 | KCNK3 (0.71) | KCNK3KCNK9MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | SCHERING AG (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | VEGFA, EGLN2, HIF1AN | KDR 8/4885KCNK3 4720/4885KCNK9 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.